Business Wire

TVP-SOLAR

27.1.2022 15:20:05 CET | Business Wire | Press release

Share
PepsiCo Implements TVP Solar Thermal Plant for Renewable Heat and Saves 140’000 M³ of Natural Gas at the Sete Lagoas Factory (MG)

PepsiCo, one of the largest food and beverage companies in the world, implemented an innovative project in its Sete Lagoas (MG) snacks operation: a solar thermal plant that captures sunlight and converts it into thermal energy for heating process water. Through this technology, it was possible to reduce natural gas consumption by 140’000 m³ in the unit - which will also reduce greenhouse gas (GHG) emissions by almost 280 tons . This number is equivalent to the planting of almost 18’000 trees.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220127005027/en/

The thermo-solar plant is made up of high-vacuum solar thermal flat panels, running automatically, without supervision and without the need for cleaning. The first results show that the plant generated about 3.9 kWh/m²/day of thermal energy during the summer months, providing hot water at 60-75°C, even in the dry climate of Sete Lagoas. The energy targets were hit. The water heated by the system is used in several factory processes. “To give an example, we use the water heated by the thermo solar system to cook the corn in our snacks. The difference is that the water is already heated to the process, so we have to use less flame time to reach the temperature we use at this stage of production” , describes Bruno Guerreiro, Sustainability Manager at PepsiCo Brazil.

With the new solar thermal plant, PepsiCo moves towards its global goal of reducing carbon emissions by 40% by 2030 (2015 baseline) and Net-zero by 2040. “It is an important innovation to use thermal energy from the solar plant in the country. With this initiative, we became more sustainable, a premise that is at the heart of the way we do business at the company, continually seeking to evolve towards a Positive Value Chain” , explained Guerreiro. According to him, the solution is scalable and should be implemented in other PepsiCo Brazil plants in the coming years, with even larger areas of solar panels.

The solar thermal plant at the Sete Lagoas site is the result of a partnership between PepsiCo and TVP Solar, a Swiss company specializing in solar thermal technology with state-of-the-art solutions. TVP Solar designs, develops, manufactures and markets high vacuum, mirrorless solar thermal collectors based on patented technology. Solar thermal energy is carbon-free and a cheaper alternative than that generated by liquid fuels.

Piero Abbate, CEO of TVP Solar, highlights that the partnership with PepsiCo is emblematic for the company, because it highlights the importance of solar thermal energy for the food and beverage industry. “We hope this will be the beginning of a long-term collaboration with PepsiCo,” says Piero.

In 2021, PepsiCo announced the launch of the PepsiCo Positive (pep+) platform, which puts sustainability at the heart of how the company creates growth and value, operating within the limits of the planet and inspiring positive change for the environment and people. As a result, sustainability starts to guide the way PepsiCo operates its business: from sourcing ingredients, manufacturing and selling its products in a more sustainable way, to inspiring people to make choices that are better for themselves and the planet. “Our solar thermal plant is another step on our journey towards sustainability. We are constantly evolving in our processes and innovating on several fronts to do our part to contain climate change, reducing greenhouse gas (GHG) emissions throughout our value chain” , said the CEO of PepsiCo Brasil Alimentos, Alex Carretero .

To learn more about the PepsiCo Positive agenda, visit

https://www.pepsico.com.br/sustentabilidade/pepsicopositive .

About PepsiCo

PepsiCo products are enjoyed more than a billion times a day by consumers in more than 200 countries and territories worldwide. PepsiCo generated more than $70 billion in global net revenue in 2020, driven by a complementary food and beverage portfolio that, in Brazil, includes PEPSI®, GATORADE®, QUAKER®, LAY'S®, DORITOS®, RUFFLES®, CHEETOS ®, KERO COCO®, H2OH!®, TODDY® among others. PepsiCo's product portfolio includes a broad range of food and beverage products, including 23 brands that generate more than $1 billion each in estimated annual sales.

PepsiCo is guided by the vision of Being the Global Leader in Convenient Food and Beverages by Winning with Purpose, which reflects our drive to win sustainably in the marketplace and embed purpose in all aspects of the business. For more information, visit www.pepsico.com.br .

About TVP Solar :

TVP Solar SA is a Swiss company which designs, develops, manufactures and markets innovative high-vacuum solar thermal collectors based on patented technology. TVP revolutionized solar thermal, decarbonizing industrial processes in large-scale deployments. TVP has been installed across 9 countries and 3 continents, supplying carbon-free renewable heat, the cheapest thermal energy cutting OPEX and CO2 emissions, while securing energy supply. For more information please visit: www.tvpsolar.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release

The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye